234 related articles for article (PubMed ID: 29288540)
1. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.
Tanaka Y; Murata-Hirai K; Iwasaki M; Matsumoto K; Hayashi K; Kumagai A; Nada MH; Wang H; Kobayashi H; Kamitakahara H; Okamura H; Sugie T; Minato N; Toi M; Morita CT
Cancer Sci; 2018 Mar; 109(3):587-599. PubMed ID: 29288540
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
Front Immunol; 2020; 11():1405. PubMed ID: 32793196
[TBL] [Abstract][Full Text] [Related]
3. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
[TBL] [Abstract][Full Text] [Related]
4. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
5. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.
Tanaka Y; Iwasaki M; Murata-Hirai K; Matsumoto K; Hayashi K; Okamura H; Sugie T; Minato N; Morita CT; Toi M
Sci Rep; 2017 Jul; 7(1):5987. PubMed ID: 28729550
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates.
Mizuta S; Tagod MSO; Iwasaki M; Nakamura Y; Senju H; Mukae H; Morita CT; Tanaka Y
ChemMedChem; 2019 Feb; 14(4):462-468. PubMed ID: 30637982
[TBL] [Abstract][Full Text] [Related]
7. PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer.
Nada MH; Wang H; Hussein AJ; Tanaka Y; Morita CT
Oncoimmunology; 2021; 10(1):1989789. PubMed ID: 34712512
[TBL] [Abstract][Full Text] [Related]
8. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.
Sugie T; Murata-Hirai K; Iwasaki M; Morita CT; Li W; Okamura H; Minato N; Toi M; Tanaka Y
Cancer Immunol Immunother; 2013 Apr; 62(4):677-87. PubMed ID: 23151944
[TBL] [Abstract][Full Text] [Related]
10. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
Front Immunol; 2021; 12():654080. PubMed ID: 34040604
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
12. Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.
Umeyama Y; Taniguchi H; Gyotoku H; Senju H; Tomono H; Takemoto S; Yamaguchi H; Tagod MSO; Iwasaki M; Tanaka Y; Mukae H
Front Immunol; 2023; 14():1058838. PubMed ID: 37006249
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy harnessing γδ T cells and programmed death-1.
Tanaka Y
Immunol Rev; 2020 Nov; 298(1):237-253. PubMed ID: 32888218
[TBL] [Abstract][Full Text] [Related]
14. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
15. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
Di Carlo E; Bocca P; Emionite L; Cilli M; Cipollone G; Morandi F; Raffaghello L; Pistoia V; Prigione I
Mol Ther; 2013 May; 21(5):1034-43. PubMed ID: 23481325
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
19. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
